ClinicalTrials.gg
Active, not recruitingNCT06707753Updated Mar 19, 2025

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

A Phase 1/2 interventional study of AL-001 in Wet Age-related Macular Degeneration (wAMD), sponsored by Beijing Anlong Biopharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Beijing Anlong Biopharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
73rd of 91
21 · median 62
Started
2023
with 13 others
Phase 1/2
18 of 106
8 open now
Primary completion
2025-08
later than 8 of 42 live
Registered
82nd of 106
by date
Lead sponsor
3 of 106
Beijing Anlong Biopharmaceutical Co., Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 73rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 1/2, reaches primary completion later than 8 of the 42 other live ones, and was the 82nd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will receive a single dose of AL-001 administered via suprachoroidal space injection.

03

Conditions studied

  • Wet Age-related Macular Degeneration (wAMD)
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 50 and ≤ 80.
  2. The study eye was diagnosed with subfoveal active choroidal neovascularization (CNV) lesions secondary to wAMD.
  3. Best Corrected Visual Acuity (BCVA) of study eye during screening, Early Treatment of Diabetic Retinopathy Study (ETDRS) letters≤73 and ≥19.
  4. The subject or their legal representative agrees to participate in this study and signs a written ICF.

Exclusion criteria

Exclusion Criteria:

  1. Non-wAMD induced CNV or macular edema in the study eye.
  2. Non-wAMD induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye.
  3. Uncontrolled glaucoma in the study eye.
  4. History of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye.
  5. Refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye.
  6. Ametropia (high myopia or high hyperopia) > 8.0D in the study eye, or significant posterior scleral staphyloma in the study eye.
  7. Malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma.
  8. None of intraocular inflammation in the study eye.
  9. Other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    AL-001 Dose 1

    Injection of low dose

    Drug: AL-001

  • Experimental
    AL-001 Dose 2

    Injection of medium dose

    Drug: AL-001

  • Experimental
    AL-001 Dose 3

    Injection of high dose

    Drug: AL-001

Interventions

  • DrugAL-001

    Administered via suprachoroidal space injection.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Week 24

Secondary outcomes

  1. Evaluate the effect of AL-001 on BCVA

    Mean change from baseline in BCVA

    Time frame: Week 52

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2025, 23 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 27, 2024
StartActual
Sep 11, 2023
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06707753
Lead sponsor
Beijing Anlong Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Sep 11, 2023
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Mar 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion